This preclinical study examines the effects of melanocortins, particularly bremelanotide, on male sexual dysfunction, specifically focusing on its ability to promote erections and enhance sexual activity behaviors. The results suggest that bremelanotide, a melanocortin receptor agonist, may offer a promising treatment for sexual dysfunction by interacting with the central nervous
The study “Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men” examined the effects of induced hypogonadism on sexual function and its relationship with cerebrospinal fluid (CSF) levels of neurosteroids and monoamine metabolites. In this comparative study, healthy male volunteers received the gonadotropin-releasing hormone agonist leuprolide acetate
This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (ED). The study found that PT-141 elicited significant erectile responses at doses greater than 7 mg, with erections occurring approximately 30 minutes post-administration. Pharmacokinetic
This review provides guidelines for designing clinical trials in male sexual dysfunction, focusing on erectile dysfunction (ED) and rapid ejaculation (RE). It outlines the necessary phases of drug development, including safety and dose-ranging studies, and emphasizes the importance of validated outcome assessments and robust statistical models. The recommendations aim to
The article “Disorders of Orgasm and Ejaculation in Men” explores the diagnosis and management of common male sexual dysfunctions, including premature ejaculation, inhibited ejaculation, anejaculation, retrograde ejaculation, and anorgasmia. It highlights the psychological, neurological, and hormonal factors contributing to these conditions and emphasizes a multidisciplinary approach to treatment, incorporating both
